ClinicalTrials.gg
CompletedNCT01705249Updated Feb 28, 2017

Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women

A Phase 4 interventional study of 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA) in Menopause and Healthy, sponsored by Novo Nordisk A/S. Completed at 19 sites in 2 countries. Open to female participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 11 years 1 month after the study started (first participant enrolled Aug 2001, registered Oct 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
191
Allocation
Non-randomized
Ages
50 Years and older
Sex
Female
01

Study summary

This study is conducted in Europe. The aim of this study is to investigate the bleeding profile after switch from Trisekvens® to Activelle® (1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)).

02

Conditions studied

  • Menopause
  • Healthy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy women
  • At least 3 months on Trisekvens® before screening period
  • Ability to understand and comply with the protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Less than 12 months or more than 36 months judged by the Investigator
  • Known, suspected, or past history of hormone dependent tumor/cancers
  • Deep venous thrombosis, active thrombophlebitis, thromboembolic disorders, cerebrovascular accidents or past history of these conditions
  • Ischemic heart disease or myocardial infarction within 6 months prior to randomization
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
191 participants (actual)

Study arms

  • Experimental
    estradiol / norethisterone acetate

    Drug: 1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)

Interventions

  • Drug1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)

    Drug pages: Estradiol · Norethindrone Acetate

    After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.

06

What researchers measure

Primary outcomes

  1. Postmenopausal women's acceptance of bleeding

    Time frame: After 24 weeks of treatment

Secondary outcomes

  1. Bleeding profile in postmenopausal women

    Time frame: After 24 weeks of treatment

  2. Acceptance of hot flushes and breast tenderness

    Time frame: After 24 weeks of treatment

07

Study locations

19 sites
  • Novo Nordisk Investigational Site
    Kristiansand, Norway
  • Novo Nordisk Investigational Site
    Kristiansund, Norway
  • Novo Nordisk Investigational Site
    Larvik, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0309, Norway
  • Novo Nordisk Investigational Site
    Trondheim, NO-7012, Norway
  • Novo Nordisk Investigational Site
    Borås, 503 32, Sweden
  • Novo Nordisk Investigational Site
    Göteborg, 411 19, Sweden
  • Novo Nordisk Investigational Site
    Göteborg, 418 33, Sweden
  • Novo Nordisk Investigational Site
    Kungsbacka, 434 30, Sweden
  • Novo Nordisk Investigational Site
    Linköping, 581 85, Sweden
  • Novo Nordisk Investigational Site
    Linköping, 582 20, Sweden
  • Novo Nordisk Investigational Site
    Linköping, 582 22, Sweden
  • Novo Nordisk Investigational Site
    Norrköping, 602 22, Sweden
  • Novo Nordisk Investigational Site
    Norrköping, 602 32, Sweden
  • Novo Nordisk Investigational Site
    Sigtuna, 193 30, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 111 37, Sweden
  • Novo Nordisk Investigational Site
    Stockholm, 111 57, Sweden
  • Novo Nordisk Investigational Site
    Södertälje, 151 23, Sweden
  • Novo Nordisk Investigational Site
    Uddevalla, 451 30, Sweden
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2001 to primary completion in Jun 2003, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2012
First posted
Oct 12, 2012
StartActual
Aug 14, 2001
Primary completionActual
Jun 6, 2003
CompletionActual
Jun 6, 2003
Last update
Feb 28, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01705249
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 12, 2012
Start date
Aug 14, 2001
Primary completion
Jun 6, 2003
Completion
Jun 6, 2003
Last update
Feb 28, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Norethindrone Acetate

Start the discussion